Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Pharm Res ; 34(3): 654-667, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28097508

RESUMO

PURPOSE: The study purposes to evaluate nanocrystalline biopolymeric nanoparticles encapsulating methotrexate and dexamethasone with high biocompatibility, enhanced therapeutic efficacy and reduced toxicity. METHODS: Chitosan nanoparticles were prepared by ionic gelation, and Methotrexate (MTX) and Dexamethasone (DEX) were loaded during the preparation and screened for their in vitro efficacy in HEK and RAW264.7 cells, ex vivo and in vivo efficacy. RESULTS: FTIR confirmed the involvement of phosphoric group of sTPP with amine groups of chitosan and also role of hydrogen bonding involved in the preparation of MTXCHNP and DEXCHNP. Controlled release patterns coupled with diffusion of drug were observed in two different buffers (PBS) at pH 7.4 and pH 5.8. The IC50 for MTXCHNP for HEK was 26.1 µg/ml and 7.7 µg/ml for RAW 264.7 cells. In DEXCHNP, the IC50 was 20.12 µg/ml for HEK and 7.37 µg/ml for RAW264.7 cells. Enhanced uptake of FITC-CHNP by RAW cells indicated internalization of nanoparticles by phagocytosis. The enhanced release of drug at lower pH justified increased cytotoxicity. Negligible ex-vivo hemolysis indicated the higher biocompatibility of the nanoparticles. 99mTc-CHNP exhibited maximum absorption in blood circulation in 3 h, followed by hepatic metabolism and renal clearance. Higher in-vivo anti-arthritic activity and antioxidant activity was observed post-intraperitoneal (i.p.) injections by both MTXCHNP and DEXCHNP when compared to MTX (0.75 mg/Kg by i.p. route) and DEX (0.2 mg/Kg/i.p./daily) per se. CONCLUSION: The nanocrystalline biopolymeric nanoparticles were stable, biocompatible and have potential to be administered through i.p. route with minimal toxicity and high efficacy.


Assuntos
Antirreumáticos/administração & dosagem , Artrite Reumatoide/tratamento farmacológico , Quitosana/química , Dexametasona/administração & dosagem , Metotrexato/administração & dosagem , Nanopartículas/química , Animais , Antioxidantes/administração & dosagem , Antioxidantes/química , Antioxidantes/farmacologia , Antirreumáticos/química , Antirreumáticos/farmacologia , Materiais Biocompatíveis , Técnicas de Cultura de Células , Linhagem Celular , Dexametasona/química , Dexametasona/farmacologia , Sistemas de Liberação de Medicamentos , Estabilidade de Medicamentos , Excipientes/química , Humanos , Concentração de Íons de Hidrogênio , Metotrexato/química , Metotrexato/farmacologia , Tamanho da Partícula , Ratos Wistar , Propriedades de Superfície , Distribuição Tecidual
2.
J Cancer Res Clin Oncol ; 142(12): 2503-2514, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27613187

RESUMO

PURPOSE: Cervical cancer is the second most prevalent cancer in women worldwide. Survival of patients has been improved by cisplatin-based chemotherapy, but its effectiveness is limited due to its adverse effects on many tissues, especially nephrotoxicity. To optimize the efficacy of CDDP, we propose a combination therapy using natural products with minimal side effects. Vitamin C being a natural antioxidant is capable of selectively targeting cancer cells at pharmacological concentrations. Vitamin C synergistically enhances the activity of chemotherapeutic agents without increasing toxicity to normal cells. Therefore, we exploited co-therapy with cisplatin and vitamin C to kill cervical cancer cells. METHODS: We elucidated the role of CDDP and VC on cervical cancer cell line (SiHa) by using cell growth assays, DNA fragmentation analysis, comet assay, in vitro morphological assessment of apoptosis (AO/EB and DAPI staining), ROS analysis by DCFDA, flow cytometry, biochemical assays (GST, GSH, NO, catalase, TPA) and Western blotting. RESULTS: Our results clearly demonstrated that CDDP and VC treatment exhibited ameliorative effect on induction of cell death by p53 overexpression and generation of hydrogen peroxide in SiHa cells, thereby reducing the dosage of CDDP required to induce cell death in cancer cells. CONCLUSIONS: These studies provide novel approaches to combat cisplatin resistance in cervical cancer.


Assuntos
Ácido Ascórbico/farmacologia , Cisplatino/farmacologia , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Proteína Supressora de Tumor p53/genética , Neoplasias do Colo do Útero/patologia , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacologia , Ácido Ascórbico/administração & dosagem , Morte Celular/efeitos dos fármacos , Morte Celular/genética , Células Cultivadas , Cisplatino/administração & dosagem , Sinergismo Farmacológico , Feminino , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Oxirredução , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/genética , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/genética , Neoplasias do Colo do Útero/metabolismo
3.
Colloids Surf B Biointerfaces ; 146: 852-60, 2016 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-27455405

RESUMO

The present work evaluates the synergistic anticancer efficacy of bioactive Hydroxyapatite (HA) nanoparticles (HA NPs) loaded with Bendamustine HCl. Hydroxyapatite is a material with an excellent biological compatibility, a well-known fact which was also supported by the results of the Hemolytic studies and a high IC50 value observed in the MTT assay. HA NPs were prepared by the chemical precipitation method and loaded with the drug via physical adsorption. In-vitro release study was performed, which confirmed the sustained release of the drug from the drug loaded HA NPs. MTT assay, Cell Uptake and FACS studies on JURKAT E6.1 cell line and in-vivo pharmacokinetic studies in Wistar rats revealed that the drug loaded HA NPs could be easily internalized by the cells and release drug in a sustained manner. The drug loaded HA NPs showed cytotoxicity similar to the drug solution at 1/10th of the drug content, which indicates a possible synergism between the activity of the anticancer drug and calcium ions derived from the carrier. An increase in intracellular Ca(2+) ions is reported to induce apoptosis in cells. Tumor regression study in Balb/c mice Ehrlich's ascites model presented a similar synergistic efficacy. The drug solution was able to decrease the tumor volume by half, while the drug loaded HA NPs reduced the tumor size by 6 times.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Cloridrato de Bendamustina/farmacologia , Carcinoma de Ehrlich/tratamento farmacológico , Sistemas de Liberação de Medicamentos , Durapatita/farmacologia , Nanopartículas/administração & dosagem , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/química , Cloridrato de Bendamustina/administração & dosagem , Cloridrato de Bendamustina/química , Carcinoma de Ehrlich/patologia , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/química , Durapatita/administração & dosagem , Durapatita/química , Humanos , Técnicas In Vitro , Células Jurkat , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Nanopartículas/química , Ratos , Ratos Wistar
4.
Int J Pharm ; 477(1-2): 454-68, 2014 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-25445525

RESUMO

The present work describes the preparation of sterically stabilize polymeric nanoparticles of mitoxantrone dihydrochloride (MTO) along with an efflux transporter (Pgp/BCRP) inhibitor that enhance the circulation time of nanoparticles and simultaneously surmount the problem of multidrug resistance (MDR). Mitoxantrone dihydrochloride being hydrophilic in nature had very low entrapment efficiency (%E.E.), thus in order to further enhance the lipophilicity and the %E.E., it was complexed with sodium deoxycholate (SDC) and this MTO-SDC-complex was used to formulate nanoparticles with/without Pgp/BCRP inhibitor by nanoprecipitation technique and was characterized for various in vitro and in vivo attributes. In vitro cell line studies were conducted on MCF7, A2780(p) and A2780(adr) cells. Furthermore, the targeting potential of hyaluronic acid (HA) coated nanoparticles for CD44 receptors was investigated using the MCF7 cell line. A reduction in the IC50 value observed with the inhibitor loaded nanoparticles in different cell lines indicated the BCRP/Pgp inhibiting ability of the formulated nanoparticles. The reduced macrophage uptake and the increased residence time in blood demonstrated the long circulating behaviour of the nanoparticles. The enhanced cellular uptake of HA coated nanoparticles in MCF7 cells revealed their targeting potential. The HA coated nanoparticles along with efflux transporter inhibitor exhibits a great potential for targeted chemotherapy in CD44 overexpressing MDR breast cancer.


Assuntos
Antineoplásicos/administração & dosagem , Portadores de Fármacos/química , Resistência a Múltiplos Medicamentos , Resistencia a Medicamentos Antineoplásicos , Mitoxantrona/administração & dosagem , Nanopartículas/química , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/antagonistas & inibidores , Animais , Antineoplásicos/farmacocinética , Antineoplásicos/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Ácido Desoxicólico/química , Ácido Desoxicólico/farmacologia , Portadores de Fármacos/farmacologia , Liberação Controlada de Fármacos , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Estabilidade de Medicamentos , Feminino , Flavanonas/química , Flavanonas/farmacologia , Hesperidina , Humanos , Ácido Hialurônico/química , Ácido Hialurônico/farmacologia , Células MCF-7 , Masculino , Microscopia Eletrônica de Varredura , Microscopia Eletrônica de Transmissão , Mitoxantrona/farmacocinética , Mitoxantrona/farmacologia , Proteínas de Neoplasias/antagonistas & inibidores , Tamanho da Partícula , Quercetina/química , Quercetina/farmacologia , Ratos Wistar , Propriedades de Superfície , Distribuição Tecidual
5.
Appl Biochem Biotechnol ; 174(3): 936-44, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24894661

RESUMO

Nanoclays may enter human body through various routes such as through the respiratory and gastrointestinal tract, skin, blood, etc. There is dearth of such studies evaluating the interaction of clay nanoparticles with human cells. In particular, the interaction of proteins and nucleic acids with nanoparticles of different aspect ratio remains a domain that is very poorly probed and understood. In the present study, we address the issue of cytotoxicity and antimicrobial attributes of two distinct nanoclay platelets namely, laponite (diameter = 25 nm and thickness = 1 nm) and montmorillonite (MMT, diameter = 300 nm and thickness = 1 nm), having different aspect ratio (25:1 vs 300:1). Cytotoxicity was assessed in both prokatyotes: Escherichia coli, eukaryotes-human embryonic kidney (HEK), and cervical cancer SiHa cell lines, and a comparative size-based analysis of the toxicity were made at different exposure time points by MTT assay. The antimicrobial activity of the nanoclays was evaluated by disc diffusion method (Kirbey-Bauer protocol). Laponite exhibited maximum efficacy as an antimicrobial agent against E. coli. Comparatively smaller size laponite could preferentially enter the cells, leading to relatively wider or larger zone of inhibition. On contradictory; laponite showed 74.67 % survival while MMT showed 89.02 % survival in eukaryotic cells at 0.00001 % (w/v) concentration. In summary, both MMT and laponite indicated cytotoxicity at 0.05 % concentration within 24 h of exposure on HEK and cervical cancer (SiHa) cell lines. The toxicity was possibly dependent on size, aspect ratio, and concentration.


Assuntos
Anti-Infecciosos/administração & dosagem , Bentonita/administração & dosagem , Nanopartículas/administração & dosagem , Silicatos/administração & dosagem , Anti-Infecciosos/efeitos adversos , Bentonita/efeitos adversos , Sobrevivência Celular/efeitos dos fármacos , Escherichia coli/efeitos dos fármacos , Células HEK293 , Humanos , Nanopartículas/química , Silicatos/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA